2016 issue 2


Volume 32, issue 2

Original article

The metabolic effects of antipsychotic medication in youth

Barbara Remberk1, Joanna Brągoszewska1, Agnieszka Jarząbek-Cudo1, Agnieszka Piróg-Balcerzak1, Filip Rybakowski1
1. Instytut Psychiatrii i Neurologii, Klinika Psychiatrii Dzieci i Młodzieży
Farmakoterapia w Psychiatrii i Neurologii 2016, 32 (2), 65–78
Date of publication: 15-08-2016
DOI: http://dx.medra.org/10.17393/fpn.2016.06.001
Keywords: antipsychotics, adverse effects, Body Mass Index


Objectives. Metabolic side effects of antipsychotic medi­cations have been observed for years and described in many studies. There is, however, a dearth of research focusing on the Polish adolescent population. The aim of this study was the assessment of metabolic side effects of antipsychotics in adolescent inpatients.

Material and methods. In 2014 and 2015, antipsychotic medication was administered in fifty nine patients hospitalised in Child and Adolescent Psychiatry Department for the first time. In each of the patients at the admission the following were assessed: body weight, body mass index (BMI), waist circumference and blood pressure and in blood samples levels of glucose, lipids, creatinine, transaminases and prolactin were tested. Thirty two patients, who had the second assessment in the course of the treatment were included in this study.

Results. During antipsychotic treatment statistically significant increase in body weight and BMI (mean 0.7 ± 0.9 and 2.1 ± 2.7 kg, respectively) were observed during the mean 4.1 ± 2.2 weeks. The increment of glucose, prolactin and lipids levels did not reach statistical significance. In all the included patients, antipsychotics were used off-label.

Conclusions. Body weight monitoring at least once a fortnight and a periodical assessment of laboratory tests and ECG seem to be crucial during psychotic treatment in children and youth. Moreover, according to current legal regulations, most of the first-line antipsychotics are prescribed off-label to children and youth. In such circumstances, monitoring of adverse effects should be essential.

Address for correspondence:
Barbara Remberk
Instytut Psychiatrii i Neurologii
ul. Sobieskiego 9, 02-957 Warszawa, Poland
phone: +48 22 21 82 247
email: bremberk@tlen.pl